Premium
Timing of disease occurrence and hepatic resection on long‐term outcome of patients with neuroendocrine liver metastasis
Author(s) -
Zhang XuFeng,
Beal Eliza W.,
Weiss Matthew,
Aldrighetti Luca,
Poultsides George A.,
Bauer Todd W.,
Fields Ryan C.,
Maithel Shishir K.,
Marques Hugo P.,
Pawlik Timothy M.
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24832
Subject(s) - medicine , resection , propensity score matching , metastasis , surgery , neuroendocrine tumors , disease , cancer
Background and Objectives The objective of the study was to evaluate the impact of timing of disease occurrence and hepatic resection on long‐term outcome of neuroendocrine liver metastasis (NELM). Methods A total of 420 patients undergoing curative‐intent resection for NELM were identified from a multi‐institutional database. Date of primary resection, NELM detection and resection, intraoperative details, disease‐specific (DSS), and recurrence‐free survival (RFS) were obtained. Results A total of 243 (57.9%) patients had synchronous NELM, while 177 (42.1%) developed metachronous NELM. On propensity score matching (PSM), patients with synchronous versus metachronous NELM had comparable DSS (10‐year DSS, 76.2% vs 85.9%, P = 0.105), yet a worse RFS (10‐year RFS, 34.1% vs 59.8%, P = 0.008). DSS and RFS were comparable regardless of operative approach (simultaneous vs staged, both P > 0.1). Among patients who developed metachronous NELM, no difference in long‐term outcomes were identified between early (≤2 years, n = 102, 57.6%) and late (>2 years, n = 68, 42.4%) disease on PSM (both P > 0.1). Conclusions Patients with synchronous NELM had a higher risk of tumor recurrence after hepatic resection versus patients with metachronous disease. The time to development of metachronous NELM did not affect long‐term outcome. Curative‐intent hepatic resection should be considered for patients who develop NELM regardless of the timing of disease presentation.